Nanobiotix H2 Earnings Call Highlights [Yahoo! Finance]
Nanobiotix S.A. - ADSs (NBTX)
Company Research
Source: Yahoo! Finance
NBTXR3 program, with the Phase III NANORAY-312 head-and-neck readout expected in H1 2027 and the randomized Phase II CONVERGE lung trial readout expected in early 2027 after a safety lead-in showing feasibility and early responses. Pivot to Curadigm : Nanobiotix is advancing its Curadigm nanoprimer platform—filing four patents, starting GMP manufacturing and CMC, running IND-enabling preclinical studies, and signing more than 20 MTAs with partners, with additional Curadigm data expected before the end of the summer. Stronger financial runway into early 2028 : An amended Janssen license that removes most Phase III funding obligations plus a non-dilutive up-to-$71M royalty financing extend cash runway into early 2028; 2025 results included EUR 32.6M revenue (largely one-time), reduced R&D to EUR 23.1M, a narrowed net loss of EUR 24.0M, and EUR 52.8M cash at year-end. Interested in Nanobiotix S.A. - Sponsored ADR? Here are five stocks we like better. Nanobiotix (NASDAQ:NBTX) exec
Show less
Read more
Impact Snapshot
Event Time:
NBTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBTX alerts
High impacting Nanobiotix S.A. - ADSs news events
Weekly update
A roundup of the hottest topics
NBTX
News
- Nanobiotix (NBTX) had its price target raised by Guggenheim from $26.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [TheStreet.com]TheStreet.com
- NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Nanobiotix GAAP EPS of -€0.50, revenue of €29.6M [Seeking Alpha]Seeking Alpha
NBTX
Sec Filings
- 3/12/26 - Form 6-K
- 2/25/26 - Form 6-K
- NBTX's page on the SEC website